Evidence map›Paper›PMID 41126651›Full record

ArticleThe journal of obstetrics and gynaecology research2025

The Expression and Clinical Significance of C1orf106 in Low-Grade Serous Ovarian Cancer.

Feifei Song, Xiaojing Chen, Tao Zhang, Xuedong Tang, Xiaodong Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of obstetrics and gynaecology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Feifei SongDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xiaojing ChenDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Tao ZhangDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xuedong TangDepartment of Obstetrics and Gynecology, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, Zhejiang, China.ORCID https://orcid.org/0009-0006-6730-9338
Xiaodong ChengDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-6073-7261

Funding

National Key Research and Development Program of China 2022YFC2704200National Key Research and Development Program of China 2022YFC2704203National Natural Science Foundation of China 82273348Science and Technology of the People's Livelihood Project of Jiaxing City 2023AY31021Science and Technology Program of Zhejiang Province 2024C03159
6 · The paper itself

Abstract

aimLow-grade serous ovarian cancer (LGSOC) is a rare subtype of ovarian cancer with distinct biological behavior. This study aimed to identify new biomarkers with potential diagnostic and prognostic value for LGSOC.

methodsGene-expression data were downloaded from the Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were identified using R. Functional enrichment analyses were conducted to determine the biological functions and signaling pathways associated with DEGs. The mitogen-activated protein kinase (MAPK) pathway-related gene, chromosome 1 open reading frame 106 (C1orf106), was selected as the target gene. Immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to verify its expression. Associations between C1orf106 expression and the clinical features of patients were analyzed using the chi-square (χ

resultsA total of 3099 upregulated and 4968 downregulated genes were identified in LGSOC. Gene set enrichment analysis (GSEA) demonstrated significant alterations in KRAS signaling and metabolic pathways between LGSOC and healthy controls. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses revealed enrichment in immune response and MAPK pathway alterations. Immunohistochemistry and qRT-PCR confirmed that C1orf106 expression in LGSOC tissues was significantly higher than in normal ovarian tissues. Clinically, high C1orf106 expression was associated with lower BMI (< 25 kg/m

conclusionsC1orf106 may serve as a promising marker for the diagnosis and prognosis of LGSOC.

Indexed as

Biomarkers, TumorCystadenocarcinoma, SerousOvarian NeoplasmsClinical RelevanceFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisBiomarkers, TumorbioinformaticsC1orf106INAVAlow‐grade serous ovarian cancersurvival analysis

Identifiers

PMID41126651
PMCPMC12547486

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.